Full Breakdown
Trump Administration Faces Multiple Legal Challenges Over Restrictions on Gender-Affirming Care
By Drooid · · How we work
Legal Challenges Overview
Four transgender youths from New Hampshire have filed a federal lawsuit contesting a new Medicaid rule that will deny coverage for puberty blockers and hormone therapy. The rule, issued by the Centers for Medicare and Medicaid Services (CMS) in August, also bars federal spending on gender-affirming surgeries for minors. Separately, the administration has asked the Supreme Court to lift a district-court order that blocks the Bureau of Prisons (BOP) from enforcing a February 2026 policy that would end hormone therapy, gender-transition surgeries, and “social accommodations” for transgender inmates. Both actions are part of the Trump administration’s effort to curtail gender-affirming care.
Background & Context
The order prompted a 2025 policy allowing limited gender-affirming care in prisons, which the BOP replaced in February 2026 with a stricter rule citing “latest scientific information” and security concerns.
Key Figures & Groups
- President Donald Trump – author of the executive order restricting gender-affirming care in prisons.
- Chris Erchull – senior staff attorney, GLBTQ Legal Advocates & Defenders, representing the New Hampshire plaintiffs.
- Dr. Frances B. Lim-Liberty – pediatric endocrinologist at Dartmouth Health, testifying on the medical impact of the Medicaid rule.
- D. John Sauer – U.S. Solicitor General, filing the emergency petition to the Supreme Court.
- Rob Bonta – California attorney general, leading a coalition of states challenging the administration’s broader impoundment of federal funds.
Timeline
- August 2025 – Executive order signed targeting “gender ideology.”
- August 2025 – CMS adopts final rule denying Medicaid coverage for puberty blockers and hormone therapy.
- February 2026 – BOP issues policy eliminating gender-affirming surgeries, hormone therapy, and social accommodations for transgender inmates.
- Sept. 25, 2026 – Administration announces a “pocket rescission” to withhold $810 million in federal funds.
- Oct 1 – New Hampshire lawsuit filed; seven states file a separate lawsuit over the rescission.
- Oct 8 – Supreme Court deadline for responses to the prison-policy request.
- Nov. 9, 2026 – End of the congressional review period for the rescission proposal.
Data & Statistics
- Plaintiffs are ages 11, 13, 15, and 15; all identify as transgender girls.
- Annual cost of gender-affirming medications without Medicaid coverage can reach $70,000 per child.
- Medicaid covers more than 73 million Americans.
- The rescission targets about $810 million, with approximately $567 million earmarked for the HHS Office of Refugee Resettlement.
Official Statements & Responses
Lim-Liberty warns that halting puberty blockers will produce “forced detransition” and irreversible masculinizing changes that hormones cannot fully reverse.
Criticism & Opposition
Legal scholars and advocacy groups describe the policies as “hostile” toward transgender people and an “arbitrary” use of executive power. Plaintiffs’ counsel notes that professional medical societies consider gender-affirming care medically appropriate for adolescents and that the rule threatens essential treatment for a vulnerable population.
What’s Next
The Supreme Court will consider the administration’s emergency request, with parties required to file responses by Oct 8. The coalition of states challenging the rescission will await the court’s decision on the constitutional claim, while the congressional review period ends on Nov 9. The outcomes will shape the availability of gender-affirming care for both Medicaid-insured minors and incarcerated transgender individuals.